Article ID Journal Published Year Pages File Type
5546911 Actualités Pharmaceutiques 2016 10 Pages PDF
Abstract
Tricyclic antidepressants were, along with imipramine and amitriptyline, the first molecules created to treat depression. More recently, serotonin reuptake inhibitors have developed significantly. Their efficacy is similar to that of tricyclics, with greater tolerance. The indications of these drugs have extended to conditions other than depression. The challenge is now to differentiate between them and attempt to identify more or less specific profiles.
Related Topics
Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Drug Discovery
Authors
, , , ,